Dmitry Balyasny’s Amphastar Pharmaceuticals AMPH Stock Holding History

Dmitry Balyasny’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-77,467	Closed	-$2.07M	–	2854
2025 Q4	$2.07M	Sell	77,467 -64,385	-45%	-$1.66M	﹤0.01%	1840
2025 Q3	$3.78M	Sell	141,852 -124,454	-47%	-$3.21M	﹤0.01%	1509
2025 Q2	$6.11M	Buy	266,306 +104,168	+64%	+$2.58M	0.01%	1188
2025 Q1	$4.7M	Buy	+162,138	New	+$5.18M	0.01%	1278
2023 Q3	–	Sell	-9,144	Closed	-$526K	–	2226
2023 Q2	$526K	Buy	+9,144	New	+$405K	﹤0.01%	1842

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Dmitry Balyasny's AMPH Position: Q1 2026 in Review

Dmitry Balyasny sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2026, closing a stake of 77,467 shares — an estimated $2.07M sold.

Dmitry Balyasny first reported a position in AMPH in Q2 2023 and held it in 5 quarters. The position peaked at $6.11M in Q2 2025. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

Dmitry Balyasny reported no remaining Amphastar Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Dmitry Balyasny sold 77,467 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $2.07M.
Dmitry Balyasny first reported a position in Amphastar Pharmaceuticals in Q2 2023 and held it in 5 quarters.
Dmitry Balyasny's Amphastar Pharmaceuticals position peaked at $6.11M in Q2 2025.
215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.